Delcath Systems Announces Publication of CHOPIN Clinical Trial Results in The Lancet Oncology Delcath Systems (Nasdaq: DCTH) announced publication of the CHOPIN randomized Phase 2 trial in The Lancet Oncology showing improved outcomes when combining percutaneous hepatic perfusion (PHP) with ipilimumab and nivolumab in metastatic uveal melanoma.Key results: 1-year PFS 54.7% vs 15.8% (HR 0.34; p=0.0002), median PFS 12.8 vs 8.3 months, median OS 23.1 vs 19.6 months (HR 0.39; p=0.0065), ORR 76.3% vs 39.5%. Higher grade ≥3 toxicity in the combination arm (82% vs 41%) and one treatment-related death were reported.

#DCTH Delcath Systems Announces Publication of CHOPIN Clinical Trial Results in The Lancet Oncology

www.stocktitan.net/news/DCTH/delcath-system...

Cancer-treatment firm Delcath swings to 2025 profit on $85M sales Non-GAAP adjusted EBITDA reached $25.1M in 2025 as Delcath ended the year with $91M cash, no debt, a $6M buyback completed and 2026 sales guided to $100M.

#DCTH Delcath Systems Reports Fourth Quarter and Full Year 2025 Results

www.stocktitan.net/news/DCTH/delcath-system...

Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results Delcath (Nasdaq: DCTH) reported preliminary, unaudited results for Q4 and full-year 2025. Total revenue is expected to be approximately $20.7M in Q4 and $85.2M for FY2025. HEPZATO KIT revenue is expected at $19.0M (Q4) and $78.8M (FY), while CHEMOSAT revenue is expected at $1.7M (Q4) and $6.4M (FY). The company repurchased 628,572 shares for $6.0M under a $25.0M buyback program. Cash and short-term investments were approximately $91.0M with no debt as of December 31, 2025. Procedure volume for HEPZATO grew ~140% in 2025 versus 2024. Final audited results and a detailed update will be released on the company’s annual call.

#DCTH Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results

www.stocktitan.net/news/DCTH/delcath-system...

#DCTH purchased today at $9.80 will outperform the #S&P500 by the end of 2026.

Delcath Systems Announces Publication of 10-Year Single-Center Experience with Percutaneous Hepatic Perfusion in Liver-Dominant Metastatic Uveal Melanoma Delcath Systems, Inc., an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication of a retrospective study by leading interventional radiologists and oncologists from Asklepios Hospital Barmbek in Hamburg, Germany. The study, titled“ Survival Outcome After Percutaneous Hepatic...

#DCTH Delcath Systems Announces Publication of 10-Year Single-Center Experience with Percutaneous Hepatic Perfusion in Liver-Dominant Metastatic Uveal Melanoma

www.stocktitan.net/news/DCTH/delcath-system...

Delcath Systems Reports Third Quarter 2025 Results and Business Highlights Delcath Systems (Nasdaq: DCTH) reported third quarter 2025 results: $20.6M total revenue, including $19.3M HEPZATO kit sales and $1.3M CHEMOSAT sales. Gross margin was 87%, net income was $0.8M, and non-GAAP adjusted EBITDA was $5.3M. Cash and investments totaled $88.9M with no debt as of September 30, 2025.Operational highlights include 25 active U.S. centers, first patient dosed in the global Phase 2 HEPZATO trial for liver-dominant metastatic colorectal cancer, and presentation of positive Phase 2 CHOPIN investigator-initiated results showing improved one-year PFS for CHEMOSAT plus ipilimumab/nivolumab. Full-year 2025 revenue guidance: $83–$85M (about 150% volume increase vs 2024) with continued positive adjusted EBITDA and cashflow each quarter.

#DCTH Delcath Systems Reports Third Quarter 2025 Results and Business Highlights

www.stocktitan.net/news/DCTH/delcath-system...

JUST IN: ( NASDAQ: #DCTH ) Delcath Systems Announces Investigator-Initiated CHOPIN Clinical Trial Meets Primary Endpoint

Just In: ( NASDAQ: #DCTH ) Delcath Systems Announces Preliminary Third Quarter 2025 Financial Results

Delcath Systems Announces Preliminary Third Quarter 2025 Financial Results Total CHEMOSAT and HEPZATO KIT revenue of approximately $20.5 million HEPZATO KIT revenue of $19.2 million CHEMOSAT revenue of $1.3 million Gross margins expected to be 87%. Net income of $0.8 million. Total CHEMOSAT and HEPZATO KIT revenue of $83 million to $85 million, reflecting an approximate 150% increase in treatment volume over 2024 Quarterly gross...

#DCTH Delcath Systems Announces Preliminary Third Quarter 2025 Financial Results

www.stocktitan.net/news/DCTH/delcath-system...

Delcath Systems Announces Investigator-Initiated CHOPIN Clinical Trial Meets Primary Endpoint Delcath Systems, Inc., an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the results of the CHOPIN randomized Phase 2 clinical trial presented by Principal Investigator and Lead Author Professor Ellen Kapiteijn, MD, from Leiden University Medical Center’ s Department of Medical Oncology...

#DCTH Delcath Systems Announces Investigator-Initiated CHOPIN Clinical Trial Meets Primary Endpoint

www.stocktitan.net/news/DCTH/delcath-system...

Delcath Systems Announces Investigator-Initiated CHOPIN Phase 2 Trial Presentation at ESMO 2025 Congress Delcath Systems (NASDAQ:DCTH), focused on liver cancer treatments, announced that results from their investigator-initiated CHOPIN Phase 2 trial will be presented at the ESMO 2025 Annual Congress. The presentation will be delivered by Principal Investigator Dr. Ellen Kapiteijn from Leiden University Medical Center.The trial evaluates the combination of systemic immunotherapy (ipilimumab and nivolumab) with Delcath's CHEMOSAT® Hepatic Delivery System for treating metastatic uveal melanoma patients. The presentation is scheduled for October 18, 2025, at 3:20 p.m. CET, and the poster will be available on Delcath's investor relations website following the ESMO embargo lift.

#DCTH Delcath Systems Announces Investigator-Initiated CHOPIN Phase 2 Trial Presentation at ESMO 2025 Congress

www.stocktitan.net/news/DCTH/delcath-system...

90-Patient Trial Launches: Delcath's HEPZATO Targets 10,000-Patient Liver Cancer Market Opportunity Delcath begins Phase 2 trial of HEPZATO for liver-dominant metastatic colorectal cancer, targeting 6,000-10,000 US patients annually. Results expected mid-2028, spanning 20+ US/EU sites.

#DCTH Delcath Systems Announces First Patient Dosed in Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Colorectal Cancer

www.stocktitan.net/news/DCTH/delcath-system...

DCTH - Delcath Sys Latest Stock News & Market Updates Delcath Systems Inc (DCTH) news hub: Track liver cancer treatment innovations, FDA updates, and clinical trial results for this pioneering drug-device developer.

#DCTH Delcath Systems Issues Full Year 2025 Guidance

www.stocktitan.net/news/DCTH/delcath-system...

#DCTH hits a milestone with its first quarterly profit in Q1 2025! HEPZATO KIT drives a 171% revenue surge to $17.8M, pushing the company to positive EBITDA. Expanding treatment centers and clinical trials signal a bright future for liver cancer treatment.
prismmarketview.com/delcath-achi...

Delcath Systems Reports First Quarter 2025 Results and Business Highlights Delcath Systems (NASDAQ: DCTH) reported strong Q1 2025 financial results, marking its first quarter of profitability. The company achieved total revenue of $19.8 million, a significant increase from $3.1 million in Q1 2024. HEPZATO KIT™ sales reached $18.0 million, while CHEMOSAT® revenue was $1.8 million. The company reported net income of $1.1 million, compared to a net loss of $11.1 million in Q1 2024, with gross margins improving to 86%. Delcath expanded its treatment network to 19 active centers, with 10 additional centers accepting referrals. The company maintained a strong financial position with $58.9 million in cash and no debt, supported by $16.2 million from warrant exercises. Additionally, Delcath received FDA clearance for a phase 2 clinical trial of HEPZATO™ in liver-dominant metastatic breast cancer.

#DCTH Delcath Systems Reports First Quarter 2025 Results and Business Highlights

www.stocktitan.net/news/DCTH/delcath-system...

FDA Green Lights Delcath's Breakthrough Liver Cancer Tech Expansion into Breast Cancer Market Major expansion into breast cancer treatment market targets 7,000 annual US patients. Multi-center trial across US and Europe to evaluate liver metastasis therapy. See timeline.

#DCTH Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer

www.stocktitan.net/news/DCTH/delcath-system...

Delcath Systems Announces Publication of Comparative Analysis from Randomized Portion of FOCUS Study in Metastatic Uveal Melanoma Delcath Systems (NASDAQ: DCTH) has published a comparative analysis from the randomized portion of their Phase 3 FOCUS study in the Annals of Surgical Oncology. The study evaluated Melphalan/Hepatic Delivery System (Melphalan/HDS) against best alternative care (BAC) in patients with unresectable metastatic uveal melanoma.Key findings from the 72 treated patients (40 Melphalan/HDS; 32 BAC) showed significant improvements with Melphalan/HDS:Median progression-free survival: 9.1 months vs 3.3 months for BACMedian overall survival: 18.5 months vs 14.5 months for BACObjective response rate: 27.5% vs 9.4% for BACDisease control rate: 80.0% vs 46.9% for BACMedian hepatic progression-free survival: 11.4 months vs 3.3 months for BACThe safety profile was consistent with prior reports, primarily showing hematologic effects, with no treatment-related deaths reported.

#DCTH Delcath Systems Announces Publication of Comparative Analysis from Randomized Portion of FOCUS Study in Metastatic Uveal Melanoma

www.stocktitan.net/news/DCTH/delcath-system...

Can Delcath's 30x Revenue Growth and FDA Trial Approval Transform Cancer Treatment? Delcath achieves 86% margins and positive Q4 EBITDA while expanding to 16 treatment centers. New FDA trial clearance opens colorectal cancer market opportunity.

#DCTH Delcath Systems Reports Fourth Quarter and Full Year 2024 Results

www.stocktitan.net/news/DCTH/delcath-system...

Major Treatment Breakthrough: NCCN Widens Access to Revolutionary Melanoma Therapy NCCN Guidelines now recommend HEPZATO KIT for broader patient group with liver-dominant melanoma, backed by strong Phase 3 trial results.

#DCTH Delcath Systems Announces Update to National Comprehensive Cancer Network Clinical Practice Guidelines for the Treatment of Metastatic Uveal Melanoma

www.stocktitan.net/news/DCTH/delcath-system...

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with bearish crossover of moving average convergence divergence signal, Mon Feb 10th - #XPEL #WPRT #UFPT #TBPH #SEVN #RZLT #PCRX #OCCI #MERC #JRVR #HRTX #ELTX #DCTH #CCSI #BDTX #UNFI #SMWB #GGT #DHT - More: crystalequityresearch.com/SmCpStr/ - #smallcap

Delcath Systems Reports Strong Q4: $15.1M Revenue, HEPZATO Sales Drive 80%+ Margins Delcath Systems achieves $37.2M annual revenue with HEPZATO KIT leading sales at $32.3M. Company maintains robust financial health with $53.2M cash and zero debt.

#DCTH Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results

www.stocktitan.net/news/DCTH/delcath-system...

Delcath Systems Raises $16.3M Through Warrant Exercise to Advance HEPZATO Melanoma Treatment Delcath Systems secures significant funding boost through warrant exercises, strengthening its position to commercialize HEPZATO treatment for uveal melanoma patients.

#DCTH Delcath Systems Announces Additional $16.3 Million in Funding From Series E and E1 Warrant Exercises

www.stocktitan.net/news/DCTH/delcath-system...

Just In: ( NASDAQ: #DCTH ) Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO(TM) in Liver-Dominant Metastatic Colorectal Cancer

#StockMarket #News

a picture of a lion with the words do not recite the deep magic to me witch i was there when it was written Alt: a picture of a lion with the words do not recite the deep magic to me witch i was there when it was written

be still, child. I’ve been fighting the Breakfast Wars since #DCTH bank when we’re still used TweetChat

Breaking News: ( NASDAQ: #DCTH ) Delcath Systems Announces Preliminary Third Quarter 2024 Revenue Results

#StockMarket #News

Just In: ( NASDAQ: #DCTH ) Delcath Systems Inc. (NASDAQ: DCTH) Sets New 52-Week High in Tuesday Session

#StockMarket #News

News; ( NASDAQ: #DCTH ) Delcath Systems, Inc. Announces Positive Outcomes from Independent Study on Hepatic Perfusion for Uveal Melanoma Patients

#StockMarket #News

Just In: ( NASDAQ: #DCTH ) Delcath Systems Announces CMS Approval for NTAP for HEPZATO KIT(TM)

#StockMarket #News

For everyone who's ever wanted to pull their hair out over old browsers' rendering quirks: http://www.pushuptheweb.com/ #DCTH